The US Bankruptcy Court conditionally approved the second amended plan of liquidation and related disclosure statement of MabVax Therapeutics Holdings, Inc. on January 10, 2019. The debtor has filed its second amended plan in the Court on January 8, 2019. As per the amended plan, Administrative Expense Claims of $0.33 million, Statutory Fees, Post-Confirmation Fees and Expenses, Professional Compensation Claims and Priority Tax Claims will be paid in full in cash on the effective date. DIP claims of $0.50 million will be paid in cash or any other treatment. Secured claims will either be paid by collateral securing or cash or any other treatment. Priority Tax Claims and non-tax claims will be paid in full in cash. 510(a), 510(b) and 510(c) subordinated Claims and inter-company claims will be deemed extinguished. General Unsecured Claims will be paid through pro rata share of available cash, while all equity interests shall be cancelled. The plan will be funded through sale of assets and available cash in hand. The final confirmation hearing is scheduled on March 5, 2020.